Page 4,881«..1020..4,8804,8814,8824,883..4,8904,900..»

Autism Treatment Under the Affordable Care Act

Posted: Published on September 27th, 2013

Lisa Ferri has two autistic sons, Nicholas and Tyler. She credits the most common autism treatment, applied behavioral analysis or ABA, with their success. "All the things that are instinctual for us and all the things that we kind of take for granted and come naturally, he had to learn absolutely everything." New York State is one of 37 states who require ABA to be covered by insurance plans, and it seems President Obama's Affordable Care Act will compliment that. "It really is a positive thing. Instead of relying on fighting the school district or other entities to cover this kind of therapy, they'll get coverage under their insurance plan like they would for any other illness," said Bryce Miler, director of the Center for Autism and Related Disorders. The Center held an information session for parents at its Fairport office Thursday. Miler says out-of-pocket costs may still be a factor for families. "The premiums are going to be higher for the better benefits," Miler said. Miler says many children require ABA treatment; about 30 hours a week. For the past few years, Ferri says schools have started to offer the services but not enough. She says private, at-home sessions … Continue reading →

Comments Off on Autism Treatment Under the Affordable Care Act

High-dose albumin treatment for acute ischaemic stroke (ALIAS) part 2: a randomised, double-blind, phase 3, placebo …

Posted: Published on September 27th, 2013

We did a randomised, double-blind, parallel-group, phase 3, placebo-controlled trial between Feb 27, 2009, and Sept 10, 2012, at 69 sites in the USA, 13 sites in Canada, two sites in Finland, and five sites in Israel. Patients aged 1883 years with ischaemic (ie, non-haemorrhagic) stroke with a baseline National Institutes of Health stroke scale (NIHSS) score of 6 or more who could be treated within 5 h of onset were randomly assigned (1:1), via a central web-based randomisation process with a biased coin minimisation approach, to receive 25% albumin (2 g [8 mL] per kg; maximum dose 750 mL) or the equivalent volume of isotonic saline. All study personnel and participants were masked to the identity of the study drug. The primary endpoint was favourable outcome, defined as either a modified Rankin scale score of 0 or 1, or an NIHSS score of 0 or 1, or both, at 90 days. Analysis was by intention to treat. Thrombolytic therapies were permitted. This trial is registered with ClinicalTrials.gov, number NCT00235495. View post: High-dose albumin treatment for acute ischaemic stroke (ALIAS) part 2: a randomised, double-blind, phase 3, placebo ... … Continue reading →

Comments Off on High-dose albumin treatment for acute ischaemic stroke (ALIAS) part 2: a randomised, double-blind, phase 3, placebo …

Supported accommodation with a SmILE

Posted: Published on September 27th, 2013

Javascript is currently disabled in your web browser. For full site functionality, it is necessary to enable Javascript. In order to enable it, please see these instructions. 7 hours ago A worldwide study into best practice accommodation design for people living with an acquired brain or spinal cord injury has been released today. Speaking at the National Acquired Brain Injury Conference in Melbourne, CEO of the Institute for Safety, Compensation and Recovery Research (ISCRR), Professor Niki Ellis, today announced the study as part of ISCRR's flagship Smart Independent Living Environments (SmILE) initiative. "This study is the first step in a research project aiming to provide evidence to drive improvement in the design of dwellings and how support is best offered to people with acquired brain or spinal cord injury," Professor Ellis. The study was led by Dean of Monash University's Faculty of Art Design & Architecture (MADA), Professor Shane Murray with the support of ISCRR. Professor Murray is an award-winning architect and academic specialising in research into contemporary housing and urban design issues. SmILE is a five year research program designed to improve the independence of people with a disability through innovations in accommodation, assistive technology and support services, such … Continue reading →

Posted in Spinal Cord Injury Treatment | Comments Off on Supported accommodation with a SmILE

Surgery to reduce Parkinson's disease symptoms performed in Houston

Posted: Published on September 27th, 2013

HOUSTON - Glen Walber went to Houston Methodist Hospital looking for hope and relief from tremors caused by Parkinson's disease that kept him from sleeping and playing his beloved tennis. "When I had tremors I couldn't play tennis. I couldn't go on vacation. I couldn't go to San Antonio Fiesta Texas. I had a hard time sleeping because my body was moving at night and around Thanksgiving I couldn't even write my own name," said the computer programmer. "Watching him not be able to play tennis I think was the hardest part," said Judy Walber, his wife of 53 years. The 75-year-old decided to take a risk to regain his quality of life and underwent surgery for deep brain stimulation at Houston Methodist -- a surgical treatment proven to reduce some of the symptoms associated with Parkinson's disease. "First step we just put electrodes. Two weeks later we put a battery. He has a rechargeable battery basically that means it will last a long time and hopefully in his case a lifetime. He has a very small pacemaker-type device that controls both electrodes on both sides of the brain. The first procedure if everything goes right is a 1-day procedure … Continue reading →

Posted in Parkinson's Treatment | Comments Off on Surgery to reduce Parkinson's disease symptoms performed in Houston

Star's recovery gives hope to Parkinson's patients

Posted: Published on September 27th, 2013

KUSA - It was something Katie Strittmatter had done an untold number of times in her life: swallow her food and beverages. But on Memorial Day Weekend in 2010, all of a sudden, she couldn't do it anymore. "I had a neckache, and I just stopped swallowing. I couldn't swallow food or water," she said. Only 31 years old at the time, Strittmatter never thought the reason she couldn't control that function was because she had Parkinson's Disease. She was shocked at the news, and the way it was delivered. "I was alone when I was diagnosed," the mom-of-two who is now 34 years old said. "They hand you a prescription, and you're out." Strittmatter says, after telling her husband about the diagnosis over the phone, she didn't talk about her disease for a year. Thousands of people, though, can understand her story. "About 17,000 Coloradans are living with Parkinson's right now," Cheryl Siefert, Executive Director of Parkinson Association of the Rockies, said. The disease causes the brain to send incorrect messages to other parts of the body, causing muscles to either resist movement or move outside of a person's control. Strittmatter experiences everything from not being able to get … Continue reading →

Posted in Parkinson's Treatment | Comments Off on Star's recovery gives hope to Parkinson's patients

Medicaid IG wants Ulster's CP agency to return $2.27M

Posted: Published on September 27th, 2013

Published: 2:00 AM - 09/27/13 KINGSTON United Cerebral Palsy of Ulster County Inc. should pay the state $2.27 million for overbilling the state Medicaid program, according to the Office of Medicaid Inspector General. The inspector general's office issued a news release Wednesday detailing its findings. They are based on the agency's audits of the UCP program's bills submitted for 2005 through 2008 and Jan. 1, 2009 through March 31, 2010. Auditors pulled a sample of the billing and examined them in detail. They found "excessive levels of missing documentation," the news release said. The most common error was treatment plans that lacked the signature of a physician. Medicaid Inspector General James C. Cox said: "Without proof that a doctor has ordered a service, no one can verify that a service should have or was provided." No money was reported stolen, a representative for the inspector general said later. The auditors used their sample to project mistakes and deficiencies for the rest of the bills from UCP. That projection tagged the overpayments at nearly $1 million in one audit and $1.27 million in the other. Linda Clark, a lawyer for UCP of Ulster County, said her client is appealing the audit … Continue reading →

Posted in Cerebral Palsy Treatment | Comments Off on Medicaid IG wants Ulster's CP agency to return $2.27M

Gel May Offer Simple Treatment for Newborns With Low Blood Sugar

Posted: Published on September 27th, 2013

By Serena Gordon HealthDay Reporter THURSDAY, Sept. 26 (HealthDay News) -- An easy-to-use gel containing dextrose -- a form of sugar -- may be an effective way to treat low blood sugar levels in newborns, new research finds. Giving infants two doses of the gel nearly halved the odds of treatment failure for low blood sugar, or hypoglycemia, compared to an inactive placebo, according to study author Jane Harding, at the University of Auckland in New Zealand, and colleagues. "Dextrose gel should be considered for first-line treatment to manage hypoglycemia in late preterm and term babies in the first 48 hours after birth," the researchers concluded in the study published online Sept. 25 in The Lancet. Low blood sugar levels (hypoglycemia) can be a serious problem in newborns. It's associated with brain injury and poor neurodevelopmental outcomes, according to study background information. Between 5 percent and 15 percent of newborns may have hypoglycemia. The incidence of hypoglycemia appears to be on the rise, the researchers noted. And, they suspect that the increase in maternal obesity and diabetes may be part of the reason. Dr. Deborah Campbell, director of the division of neonatology at the Children's Hospital at Montefiore in New … Continue reading →

Posted in Brain Injury Treatment | Comments Off on Gel May Offer Simple Treatment for Newborns With Low Blood Sugar

Attacked man unaware of brain injury

Posted: Published on September 27th, 2013

27 September 2013 Last updated at 10:05 ET The victim of an unprovoked attack almost died after not realising the seriousness of his injury, for more than a month. The 53-year-old man was hit in the face and head by three men in East Grinstead in July, but did not report it. Then, while on a family holiday abroad in August, he started suffering headaches before becoming unable to recognise family and friends. He later underwent surgery for a life-threatening brain injury. A Sussex Police spokesman said when the man returned from holiday, he went for a scan and on 13 September, was rushed to Hurstwood Park neurological unit in Haywards Heath and the attack was reported to the force. The victim is now recovering from emergency brain surgery. The three attackers, described as white and in their early 20s, had been sitting on a bench with a woman outside the Energie fitness club in London Road before the assault. Det Con Karrie Bohanna said: "This was a nasty unprovoked attack that could have proved fatal. "If the victim had not been with his family when his condition worsened he might not have got the treatment he needed in time." … Continue reading →

Posted in Brain Injury Treatment | Comments Off on Attacked man unaware of brain injury

Opexa to Present at the Aegis Capital Corp. 2013 Healthcare Conference

Posted: Published on September 27th, 2013

THE WOODLANDS, Texas--(BUSINESS WIRE)-- Opexa Therapeutics, Inc. (OPXA), a biotechnology company developing Tcelna, a patient-specific T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced that Neil K. Warma, Opexas President and Chief Executive Officer, will deliver a corporate presentation at the Aegis Capital Corp. 2013 Healthcare Conference. The conference will be held September 25-28th at The Encore at Wynn Las Vegas. Opexas presentation will occur at 8:30 a.m. (PDT) on Friday, September 27, 2013, and will include an overview of the Companys ongoing clinical development program for Tcelna, the Companys lead therapy for MS. About Opexa Opexas mission is to lead the field of Precision Immunotherapy by aligning the interests of patients, employees and shareholders. The Companys leading therapy candidate, Tcelna, is a personalized T-cell immunotherapy currently in a Phase IIb clinical development program (the Abili-T trial) for the treatment of Secondary Progressive Multiple Sclerosis. Tcelna is derived from T-cells isolated from the patients peripheral blood, expanded ex vivo, and reintroduced into the patients via subcutaneous injections. This process triggers a potent immune response against specific subsets of autoreactive T-cells known to attack myelin. About Multiple Sclerosis (MS) Multiple Sclerosis is a chronic, inflammatory condition of the central … Continue reading →

Posted in MS Treatment | Comments Off on Opexa to Present at the Aegis Capital Corp. 2013 Healthcare Conference

ENDECE Neural Receives National MS Society Funding to Advance Myelin Repair Compound

Posted: Published on September 27th, 2013

MEQUON, Wisc.--(BUSINESS WIRE)-- ENDECE Neural today announced that it has entered into a sponsored research agreement for funding from the National Multiple Sclerosis Society through Fast Forward. Under the terms of the agreement ENDECE Neural will receive funding to advance the preclinical development of the companys lead compound, NDC-1308. If successfully developed into a therapeutic, NDC-1308 could provide physicians with a treatment to restore and repair the protective covering surrounding axons (nerve fibers) in the brain and spinal cord. ENDECE Neural will use the $225,000 in funding to validate preliminary data suggesting that NDC-1308 can restore and repair the axons protective covering, which is known as the myelin sheath. NDC-1308 demonstrated the ability to significantly remyelinate the myelin sheath in mice. The validation study will repeat the testing using an optimized formulation to determine how robustly NDC-1308 can stimulate remyelination in different regions of the mouse brain. ENDECE Neural also announced today that researchers will present data from preclinical trials of NDC-1308 at the 29th Congress of the European Committee for Research and Treatment in Multiple Sclerosis (ECTRIMS) in Copenhagen, Denmark. The oral presentation, titled, NDC-1308 induces remyelination in experimental models of multiple sclerosis, is scheduled for Friday, Oct. 4 … Continue reading →

Posted in MS Treatment | Comments Off on ENDECE Neural Receives National MS Society Funding to Advance Myelin Repair Compound

Page 4,881«..1020..4,8804,8814,8824,883..4,8904,900..»